SLAMF7 and Miyoshi myopathy: In previous work, we have demonstrated that T cells expressing a SLAMF7 CAR (Fig. 4B) are substantially more potent against MM than the anti-SLAMF7 antibody elotuzumab in preclinical models in vitro and in vivo [48] and, therefore, the results of the CARAMBA clinical trial are eagerly awaited.